Abstracts Archive - Page 1125 of 2425 - ACR Meeting Abstracts

Abstract Number: 1806 • 2018 ACR/ARHP Annual Meeting
Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road
Ertugrul Cagri Bolek, Alper Sari, Levent Kilic, Ali Akdogan, Meryem Asli Tuncer and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey
Background/Purpose: Spinal cord involvement may occur in the course Behcet's Disease (BD). It may present with distinct manifestations such as sphincter and/or sexual dysfunction. We…
Abstract Number: 1807 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease
Ertugrul Cagri Bolek, Alper Sari, Berkan Armagan, Abdulsamet Erden, Levent Kilic, Umut Kalyoncu, Meryem Asli Tuncer, Sedat Kiraz and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey
Background/Purpose: Neurological involvement (NBD) is a rare complication of BD. Although NBD is not common in the course of BD, it is related with significant…
Abstract Number: 1808 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis
Aycan Gokturk¹, Sinem Nihal Esatoglu¹, Yesim Ozguler¹, Ersan Atahan², Benan Musellim², Vedat Hamuryudan¹, Hasan Yazici³ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey, ³Istanbul Academic Hospital, Istanbul, Turkey
Background/Purpose: Superior vena cava syndrome (SVCS), is a medical emergency and can also be seen in Behçet’s syndrome (BS). Contrary to the severe outcome seen…
Abstract Number: 1809 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients
Gul Guzelant¹, Yilmaz Ozyazgan², Cem Mat³, Vedat Hamuryudan¹, Hasan Yazici¹ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey
Background/Purpose: The usual onset of Behçet syndrome (BS) is in the 3. decade. Older age-onset defined as fulfilling the International Study Group (ISG) criteria after…
Abstract Number: 1810 • 2018 ACR/ARHP Annual Meeting
Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts
Floor Kerstens¹, Christopher J. Swearingen², Franktien Turkstra¹ and Yusuf Yazici³, ¹Amsterdam Rheumatology & Immunology Centre - Reade, Amsterdam, Netherlands, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome (BS) is formally diagnosed using the International Study Group (ISG) criteria, where recurrent oral ulceration and any two other symptoms (recurrent genital…
Abstract Number: 1811 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
Jing Shi¹, Chan Zhao², Jiaxin Zhou³, JinJing Liu¹, Fei Gao², Xiaofeng Zeng⁴, Meifen Zhang² and Wenjie Zheng¹, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ⁴Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Uveitis is one of the leading causes of morbidity in Behcet’s patients which may result in irreversible vision loss. Evidence is accumulating that interferon…
Abstract Number: 1812 • 2018 ACR/ARHP Annual Meeting
Characterization and Prevalence of Morbus Behçet in Switzerland
Sabine Adler¹, Rahel Villiger², Lukas Buetikofer³ and Peter M. Villiger⁴, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Rheumatology, Immunology and Allergology, University Hospital Bern, Switzerland, Bern, Switzerland, ³Clinical Trials Unit, University of Bern, Bern, Switzerland, ⁴Rheumatology and Clin Immunol, Bern, Switzerland
Background/Purpose: To evaluate the clinical presentation of patients with Morbus Behçet (MB) in a cohort from Switzerland and to calculate the prevalence of MB in…
Abstract Number: 1813 • 2018 ACR/ARHP Annual Meeting
Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
Muhammed Aydin¹, Bahar Artim-Esen¹, Murat Inanc², Lale Ocal¹ and Ahmet Gül¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Behçet disease (BD) is a multisystem inflammatory disorder characterized by recurrent manifestations in mucocutaneous tissues, eyes, joints, blood vessels, intestines and brain. Since there…
Abstract Number: 1814 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series
Yesim Ozguler¹, Gulen Hatemi², Firat Cetinkaya³, Koray Tascilar⁴, Serdal Ugurlu¹, Emire Seyahi¹, Hasan Yazici¹ and Melike Melikoglu¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, ⁴Numune Research and Teaching Hospital, Ankara, Turkey
Background/Purpose: Lower extremity deep vein thrombosis (LEDVT) is a disabling complication of Behcet’s syndrome (BS). Relapses are frequent and cause permanent disability due to post-thrombotic…
Abstract Number: 1815 • 2018 ACR/ARHP Annual Meeting
Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center
Jiaxin Zhou¹, Jing Shi², Xiuhua Wu², JinJing Liu² and Wenjie Zheng², ¹Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To analyze the clinical features of patients with Behcet’s disease(BD) complicated with aneurysmal lesions. Methods: We retrospectively reviewed the clinical data of patients with…
Abstract Number: 1816 • 2018 ACR/ARHP Annual Meeting
Five-Year Outcome of Operative and Nonoperative Management of Meniscal Tear in the Presence of Osteoarthritic Changes
Jeffrey N. Katz¹, Swastina Shrestha², Elena Losina³, Lisa A. Mandl⁴, Bruce Levy⁵, Kurt Spindler⁶ and Jamie E. Collins⁷, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopaedics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Orthopedics, Mayo Clinic, Rochester, MN, ⁶Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH, ⁷Department of Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA
Background/Purpose: While recent trials have examined short-term (~ 2 year) outcomes of surgical and nonoperative treatment of meniscal tear in the setting of osteoarthritis there…
Abstract Number: 1817 • 2018 ACR/ARHP Annual Meeting
MicroRNA-128 Impairs Cartilage Integrity and Deteriorates Osteoarthritis Pathogenesis through Deregulating Chondrocyte Autophagy
Feng-Sheng Wang¹, Wei-Shiung Lian², Yi-Chih Sun¹, Jih-Yang Ko³ and Yu-Shan Chen¹, ¹Core Facility for Phenomics & Diagnostics, Department of Medical Research, Core Facility for Phenomics & Diagnostics, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan, ²Core Facility for Phenomics & Diagnostics, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan, ³Department of Orthopedic Surgery, Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan
Background/Purpose: Autophagy gets rids of unwanted proteins or organelle keeping cells to stay functional upon encountering adverse stresses. While non-coding microRNAs interfere with mRNA targets…
Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting
Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Osvaldo D. Messina⁵, Jorge Morales-Torres⁶, Ronald Emkey⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aries, Argentina, ⁶Hospital Aranda de la Parra, Leon, Mexico, ⁷Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
Abstract Number: 1819 • 2018 ACR/ARHP Annual Meeting
MUC5B promoter Variant rs35705950 Is a Risk Factor for Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Joyce Sujin Lee², Esther Ebstein¹, Hiroshi Furukawa³, Evgenia Dobrinskikh⁴, Steven Gazal⁵, Caroline Kannengiesser⁵, Sébastien Ottaviani¹, Shomi Oka⁶, Shigeto Tohma⁷, Naoyuki Tsuchiya⁸, Jorge Rojas-Serrano⁹, Montserrat I. González-Pérez⁹, Mayra Mejía⁹, Ivette Buendía-Roldán⁹, Ramcés Falfan-Valencia¹⁰, Enrique Ambrocio-Ortiz¹⁰, Effrosyni Manali¹¹, Spyros A. Papiris¹¹, Theofanis Karageorgas¹², Dimitrios Boumpas¹², Katarina Antoniou¹³, Coline H.M. van Moorsel¹⁴, Joanne van der Vis¹⁴, Yaël A. de Man¹⁴, Jan C. Grutters¹⁴, Yaping Wang¹⁵, Raphaël Borie¹⁶, Lidwine Wemeau-Stervinou¹⁷, Benoit Wallaert¹⁸, René-Marc Flipo¹⁹, Hilario Nunes²⁰, Dominique Valeyre²⁰, Nathalie Saidenberg²¹, Marie-Christophe Boissier²², Sylvain Adam-Marchand²³, Aline Frazier²⁴, Pascal Richette²⁵, Yannick Allanore²⁶, Jean Sibilia²⁷, Claire Dromer²⁸, Christophe Richez²⁹, Thierry Schaeverbeke³⁰, Huguette Lioté³¹, Gabriel Thabut³², Nadia Nathan³³, Serge Amselem³⁴, Martin Soubrier³⁵, Vincent Cottin³⁶, Annick Clément³³, Kevin D. Deane³⁷, Avram D. Walts⁴, Tasha Fingerlin³⁸, Aryeh Fischer³⁹, Jay H. Ryu⁴⁰, Eric L. Matteson⁴¹, Timothy B. Niewold⁴², Deborah Assayag⁴³, Andrew Gross⁴⁴, Paul Wolters⁴⁵, Marvin I. Schwartz⁴⁶, V. Michael Holers⁴⁷, Joshua J. Solomon⁴⁸, Tracy Doyle⁴⁹, Ivan O. Rosas⁵⁰, Cornelis Blauwendraat⁵¹, Mike A. Nalls⁵², Marie-Pierre Debray¹⁶, Catherine Boileau⁵, Bruno Crestani¹⁶, David A. Schwartz⁴ and Philippe Dieude¹⁶, ¹Rhumatologie, Hôpital Bichat - Claude Bernard, Paris, France, ²SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, ³University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, ⁴Department of Medicine, University of Colorado School of Medicine, Aurora, CO, ⁵Génétique, Hôpital Bichat - Claude Bernard, Paris, France, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hopsital, Sagamihara, Japan, ⁷Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ⁸Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁹Interstitial Lung Disease & Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ¹⁰HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ¹¹2nd Pulmonary Medicine Department, University Hospital of Athens "Attikon", Athens, Greece, ¹²Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, University Hospital of Athens "Attikon", Athens, Greece, ¹³PS Department of Respiratory Medicine & Laboratory of Molecular & Cellular Pneumonology, University of Crete, Crete, Greece, ¹⁴St Antonius ILD center of excellence, St Antonius ziekenhuis, Nieuwegein, Netherlands, ¹⁵Department of Medical Genetics, Nanjing University School of Medicine, Nanjing, China, ¹⁶Université Paris-Diderot, Paris, France, ¹⁷Pneumologie, CHRU de Lille, Lille, France, ¹⁸Pneumology, CHRU, Lille CEDEX, France, ¹⁹Hôpital Roger Salengro, Lille, France, ²⁰Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ²¹Rhumatologie, Hôpital Avicenne, Paris, France, ²²74 rue Marcel Cachin, INSERM, Bobigny, France, ²³Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ²⁴Rhumatologie, Hôpital Lariboisière, Paris, France, ²⁵Rheumatology, Université Paris Diderot, Paris, France, ²⁶Rhumatologie A, Hôpital Cochin, Paris, France, ²⁷Université de Strasbourg, Strasbourg, France, ²⁸Imagerie Thoracique et Cardiovasculaire, CHU Bordeaux, Bordeaux, France, ²⁹Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ³⁰Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, ³¹Pneumologie A, Hôpital Tenon, Paris, France, ³²Pneumologie B, Hôpital Bichat - Claude Bernard, Paris, France, ³³Pneumologie pédiatrique, Hôpital Trousseau, Paris, France, ³⁴Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France, ³⁵Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³⁶Lyon Louis Pradel, Lyon, France, ³⁷Division of Rheumatology, University of Colorado Denver, Aurora, CO, ³⁸Department of Biomedical Research, National Jewish Health, Denver, CO, ³⁹Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴⁰Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴¹Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴²Colton Center for Autoimmunity, New York University School of Medicine, New York, NM, ⁴³McGill University, Department of Medicine, Montreal, QC, Canada, ⁴⁴Department of Medicine, University of California, San Francisco, CA, ⁴⁵Pulmonary Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, ⁴⁶University of Colorado School of Medicine, Department of Medicine, Aurora, CO, ⁴⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴⁸Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, ⁴⁹Brigham and Women's Hospital, Boston, MA, ⁵⁰BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁵¹Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, ⁵²Data Tecnica International, Glen Echo, MD
Background/Purpose: Given phenotypic similarities between rheumatoid arthritis–associated interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), we hypothesized that the strongest risk factor for the…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].